Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


04. February 2020 | 05:50 CET

Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal

  • Cannabis
Photo credits: pixabay.com

From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other pharmaceutical products. The market and attitudes towards cannabis are now changing. Doctors, patients, companies and investors see opportunities to profit from this development.

time to read: 1 minutes by Mario Hose
ISIN: CA30207T1049 , CA05156X1087 , US88688T1007


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Education is the key to success

Education and research are often the beginning of a success story. In order for development to progress, knowledge and education are an elementary basis for medical change with cannabis. Doctors, patients and companies must work together to test and evaluate the effects of cannabis in medicine.

With increasing experience and information in databases the acceptance of cannabis in medicine will increase. Thus the use of medical cannabis preparations can be suggested by physicians or simply demanded by patients.

Improvement of the quality of life

The use of and experiences with cannabis products are characterized by objective and subjective characteristics. For example, a cannabis product may cause a patient to sleep much better but not to feel any improvement in pain relief. The bottom line, however, is that the quality of life has subjectively increased due to improved sleep.

Such developments in practice ensure that cannabis products are accepted in medicine. In this context, however, it is important that patients have easy access to medical cannabis products and also that doctors know what they are prescribing for which therapies.

Opportunities for investors

Also the companies invest in the development of the cannabis market and here especially experience counts. Aurora Cannabis, EXMceuticals and also Tilray have different approaches and strategies to conquer the market for cannabis products.

For investors there is the opportunity to participate in the listed companies to be part of it. Even if the share prices of most cannabis companies have been declining in recent months, the trend in use and therapy will continue. It will probably only be a matter of time when this development will be reflected in the stock market prices again.

Portugal as cannabis centre

EXMceuticals, a manufacturer of high quality cannabis extracts for use in the pharmaceutical and nutraceutical industry as well as in therapy and cosmetics, announced yesterday that Prf. Dr. Eurico Castro Alves has been appointed to the company's advisory board.

Commenting on the appointment, Jonathan Summers, CEO of the company, said: "He and EXM share a common goal to establish Portugal as a centre for medical Cannabis healthcare and science. The next step is to have in operation, and licensed, a high-quality ingredients factory that will produce to medical standards and have many industrial applications.”


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. March 2021 | 09:16 CET | by Stefan Feulner

NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!

  • Cannabis

The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!

Read

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

15. July 2020 | 12:23 CET | by Mario Hose

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read